- BioDlink convenes a peer advisory event bringing together biotech CEOs, MNC leaders and researchers to discuss innovation and collaboration strategies

- Integrated one-stop technology platform helps innovative biotech companies launch life-saving therapies with greater speed, scale, and efficiency

BioDlink, a leading global CDMO, hosted its 2025 Peer Advisory Board on June 26, 2025, spotlighting China’s dynamic clinical trial and CDMO landscape as a global springboard for biotech innovation. This event, themed “Advancing Innovative Drugs Together Worldwide,” BioDlink, alongside partners BioPlus, Cobetter, NanoMicro Technology, and Hengyu Biotech, convened top biotech CEOs, MNC executives, research leaders and investment management to discuss how innovative biotech companies could leverage China’s rapidly evolving clinical trial and CDMO ecosystem.

Dr. Jun Liu, CEO and Executive Director of BioDlink, noted that China's biopharmaceutical industry is accelerating its transition to contribute globally and called on innovative biotech, CDMOs and international partners to strengthen innovation and cross-border collaboration. “Going global doesn’t mean going it alone,” he said. “Biotech innovators are strong in taking ideas from zero to one，while we’re excels at scaling from one to ten.By leveraging our one-base, end-to-end antibody drugs and bioconjugates CDMO platform, we aim to combine strenths —  enabling new therapies to reach patients faster, more efficiently, and at scale.”

Backed by 15 years of operational excellence, BioDlink combines advanced biologics development and manufacturing capabilities with a synergistic industrial ecosystem. Dr. Jun Liu notes that competitive edge stems from its one-base, end-to-end streamlined platform for antibody drugs and bioconjugates focused on  three core customer needs: quality, speed, and cost efficiency. “Going global is a race against time,” said Dr. Jun Liu. “Our clients don’t just need high quality and fast delivery — they need a partner who can achieve quality, speed, and cost-efficiency all at once. That’s where A truly makes a difference — by solving the real-world complexities of globalization.” He added, “The foundation of our global journey lies in building international talent and forging strong global partnerships.”

Building on a strong foundation of strict quality systems and CMC compliance, while leveraging China’s efficient R&D environment and favorable regulatory dynamics, BioDlink enables biotech companies to fast-track clinical programs, optimize development budgets, and undertake global regulatory filings while complying with global quality standards.

Professor Jifang Gong, Deputy Director of Phase I Clinical Ward at Peking University Cancer Hospital, provided a recap of ASCO clinical advances for gastrointestinal tumors and the potential impact on global solid tumor treatment.  As China's clinical capabilities, policy support, and R&D efficiency advance, the resolution of unmet global clinical needs is accelerated, with wider international attention for local research achievements.

To facilitate better understanding to advance global biotech ecosystems, Dr. Zhi Yi Xie, Vice President of Global Clinical Research and Development for Asia-Pacific at BioNTech, shared insights on the state of play and clinical development strategies for bispecific antibodies and ADCs.

Debating the future: Antibodies vs. ADCs and the billion-dollar question

Two teams of industry leaders representing antibodies and ADCs engaged in a debate around two major topics: “How to attract global principal investigators to undertake clinical trials?” and “How to win billion-dollar cooperations with MNCs?”

What emerged was not a winner, but a consensus: the next wave lies in convergence. Looking at the latest industry developments, the convergence of traditional antibody therapies and ADCs is emerging as a key direction for addressing unmet clinical needs. Through precise delivery mechanisms, such convergence offers patients more effective treatment options.

A globalization playbook

In a strategy roundtable, participants exchanged insights on ADC, TCE, and dual/multi-antibody project initiation strategies, innovative drug development target selection best practices, U.S. clinical trial navigation tips, how to evaluate overseas clinical CROs as well as the latest CMC and quality management client requirements.

This discussion eventually coalesced around four key pillars for biotech globalization:

·       Design globally from day one: Align development with international unmet needs.

·       Clinical development: Differentiated clinical designs offer a global competitive edge.

·       Secure quality through CMC: Build an independent and globally compliant supply chain.

·       Ecosystem collaboration: Build alliances with CDMOs and other ecosystem partners.

In addition, BioDlink partners indicated that ongoing collaboration is built upon a shared emphasis on quality, speed, and innovation to meet client needs amid constant technology advances and regulatory updates.

This event also marked the official launch of BioDlink’s English-language brand with Bio-representing biopharma excellence in large molecules, empowering global health, D-representing drug-driven and innovation-focused, specializing in ADC/XDC development and manufacturing; and honoring its legacy with capitalized first letter of "Dongyao" , and link representing precise biconjugation and linker technology to connect the world to a BioDlink-centric ecosystem.

This new identity underscores the company’s core specializations in large molecules, including monoclonals, bispecifics, ADCs, and XDCs, as well as its commitment to innovation, adherence to compliance and quality standards, industry connectivity, and ecosystem co-creation.

Looking forward, BioDlink aims to be a strategic partner of choice for biotech startups and pharmaceutical innovators worldwide — a conduit for translating innovative research into global therapeutic impact.